Hologic, Inc. (NASDAQ:HOLX) Shares Sold by First Hawaiian Bank

First Hawaiian Bank decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 52.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,028 shares of the medical equipment provider's stock after selling 18,933 shares during the quarter. First Hawaiian Bank's holdings in Hologic were worth $1,228,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Wolff Wiese Magana LLC purchased a new stake in shares of Hologic in the third quarter valued at about $25,000. General Partner Inc. purchased a new stake in Hologic in the 4th quarter valued at approximately $26,000. Groupama Asset Managment grew its holdings in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after buying an additional 2,999 shares during the last quarter. Sunbelt Securities Inc. acquired a new stake in Hologic during the 2nd quarter valued at $37,000. Finally, First Horizon Advisors Inc. increased its position in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after buying an additional 134 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Trading Down 1.4 %

HOLX stock traded down $1.04 during trading on Friday, reaching $71.70. 2,147,897 shares of the stock traded hands, compared to its average volume of 1,978,683. The firm has a market capitalization of $16.27 billion, a PE ratio of 21.53, a P/E/G ratio of 2.32 and a beta of 0.97. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The business's 50 day moving average price is $76.09 and its 200-day moving average price is $78.47. Hologic, Inc. has a 52-week low of $70.36 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.01. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company's revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.89 EPS. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business's stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.75% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Mizuho reduced their price objective on Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a research report on Tuesday, November 5th. Citigroup lowered shares of Hologic from a "buy" rating to a "neutral" rating and reduced their target price for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Leerink Partners lowered their price target on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a report on Tuesday, October 8th. UBS Group upped their price objective on shares of Hologic from $84.00 to $90.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Finally, Jefferies Financial Group assumed coverage on shares of Hologic in a research note on Tuesday, December 10th. They issued a "hold" rating and a $85.00 target price for the company. Six research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $89.50.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.